Preliminary Safety and Antileukemic Activity of Sonrotoclax (BGB-11417), a Potent and Selective **BCL2** Inhibitor, in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Pau Montesinos,¹ Paul Cannell,² Jake Shortt,³ Teng Fong Ng,⁴ David M. Swoboda,⁵ Sophie Leitch,⁶ Chun Yew Fong,⁷ Uwe Platzbecker,⁸ Andrew H. Wei,⁹ Si Cheng,¹⁰ Adam Greenbaum,¹¹ Yu Liu,¹² Kendra Sweet,¹¹ Amit Agarwal,¹¹ Courtney DiNardo¹³

¹Hospital Universitari I Politècnic La Fe, Valencia, Spain; ²Fiona Stanley Hospital, Murdoch, WA, Australia; ³Monash Health and Griffith University, Queensland, Waitemata, Auckland, New Zealand; ⁴Gold Coast University, Queensland, New Zealand, New Zealand; ⁴Gold Coast University, Queensland, New Zealand; ⁴Gold Coast University, Queensland, New Zealand; ⁴Gold Coast University, Queensland; ⁴Gol ⁷Austin Health, Melbourne, VIC, Australia; ¹⁰BeiGene USA, Inc, San Mateo, CA, USA; ¹²BeiGene (Beijing) Co, Ltd, Beijing, China; ¹³MD Anderson Cancer Center, Houston, TX, USA ¹⁴BeiGene (Beijing) Co, Ltd, Beijing, China; ¹³MD Anderson Cancer Center, Houston, TX, USA ¹⁴BeiGene (Beijing) Co, Ltd, Beijing, China; ¹³MD Anderson Cancer Center, Houston, TX, USA ¹⁴BeiGene (Beijing) Co, Ltd, Beijing, China; ¹⁴BeiGene (Beijing) Co, Ltd, Beijing) Co, Ltd, Beijing, China; ¹⁴BeiGene (Beijing) Co, Ltd, Beijing, China; ¹⁴BeiGene (Beijing) Co, Ltd, Beijing) Co, Ltd, Beijing, China; ¹⁴BeiGene (Beijing) Co, Ltd, Beijing, China; ¹⁴BeiGene (Beijing) Co, Ltd, Beijing) Co, Ltd, Beijing, China; ¹⁴BeiGene (Beijing) Co, Ltd, Beijing) Co, Ltd, Beijing, China; ¹⁴BeiGene (Beijing) Co, Ltd, Beijing) Co, Ltd, Beijing, China; ¹⁴BeiGene (Beijing) Co, Ltd, Beijing) Co, Ltd, Beijing, China; ¹⁴BeiGene (Beijing) Co, Ltd, Beijing) Co, Ltd, Beijing, China; ¹⁴BeiGene (Beijing) Co, Ltd, Beijing) Co, Ltd, Beijing, China; ¹⁴BeiGene (Beijing) Co, Ltd, Beijing) Co, Ltd, Beijing, China; ¹⁴BeiGene (Beijing) Co, Ltd, Beijing) Co, Ltd, Beijing, China; ¹⁴BeiGene (Beijing) Co, Ltd, Beijing) Co, Ltd, Beijing, China; ¹⁴BeiGene (Beijing) Co, Ltd, Beijing) Co, Ltd, Beijing, China; ¹⁴BeiGene (Beijing) Co, Ltd, Beijing) Co, Ltd, Beijing)


INTRODUCTION

- Acute myeloid leukemia (AML) is the most common acute form of leukemia in adults and has an aggressive disease course^{1,2}
- Although treatment with the B-cell lymphoma 2 (BCL2) inhibitor venetoclax has improved outcomes in some patients with newly diagnosed AML,³ venetoclax is not approved in relapsed/refractory (R/R) AML⁴
- Sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, is more selective and a more pharmacologically potent inhibitor of BCL2 than venetoclax, with a shorter half-life and no accumulation⁵
- Here, we present the preliminary safety and antileukemic activity of sonrotoclax + azacitidine in R/R AML in BGB-11417-103, a phase 1b/2 study

METHODS

- BGB-11417-103 (NCT04771130; EudraCT: 2021-003285-12) is an ongoing, global, multicenter, dose-finding and -expansion study evaluating sonrotoclax ± azacitidine in patients with AML, myelodysplastic syndromes (MDS), or MDS/myeloproliferative neoplasms (Figure 1)
- The primary and key secondary endpoints were safety per CTCAE v5.0 and CR + CR with partial hematologic recovery (CRh) rate per the 2017 European LeukemiaNet criteria and partial hematology recovery criteria for AML
- Sonrotoclax was administered orally once daily for a limited duration with an initial 4-day ramp-up to mitigate potential risk of tumor lysis syndrome (TLS), and azacitidine (75 mg/m² for 7 days/cycle) was administered subcutaneously or intravenously

Figure 1. BGB-11417-103 Study Design




^a HMA failure received \geq 1 cycle of HMA and had PD or no PR or better hematologic improvement after 4 cycles of >75% of planned dose. ^b Or cycle 2 initiation. ^cAs a precautionary measure for TLS monitoring, patients were hospitalized during the ramp-up period. ^d Safety monitoring committee reviews available data to determine dose escalation in part 1, dose expansion to part 2, and the final RP2D to start part 3. CYP3A4, cytochrome P450 3A4; HMA, hypomethylating agent; non-APL, nonacute promyelocytic leukemia.

RESULTS

- As of March 31, 2024, a total of 51 patients with R/R AML were enrolled and had received
- sonrotoclax + azacitidine treatment and 4 (8%) remain on treatment (**Figure 2**) • In all patients with R/R AML, the median age was 60 years and the median number of prior lines of
- therapy was 2 (**Table 1**)
- The median number of treatment cycles was 2, with the longest average cycle duration
- (median, 42.3 days) in the azacitidine + sonrotoclax 320 mg x 21 day cohort (**Table 2**)
- The median dose intensity relative to the assigned dose of sonrotoclax was >80%, except in the azacitidine + sonrotoclax 160 mg x 21 day cohort

Figure 2. Patient Disposition



Data cutoff: March 31, 2024. ^a The efficacy-evaluable population included patients who (1) completed ≥1 treatment cycle (initiated the second cycle) or 42 days, whichever is earlier, or discontinued treatment during the first cycle or (2) had \geq 1 response assessment. ^b Defined as evidence for an increase in bone marrow blast percentage and/or increase in absolute blast counts in the blood, both per ELN2017 response criteria. ^c Hematologic relapse (after CR/CRi) defined as bone marrow blasts ≥5%, reappearance of blasts in the blood, or development of extramedullary disease. CRi, CR with incomplete hematologic recovery; ELN, European LeukemiaNet.

Table 1. Baseline Patient Characteristics	•	The most common TEAE class leading to treatment discontinuation was infections and infections $(a_{1}a_{2}a_{3}a_{3}a_{4}a_{3}a_{3}a_{3}a_{3}a_{3}a_{3}a_{3}a_{3$	 Sonrotoclax + azacitidine combination treatment was generally well tolerated in patients with R/R AML without prior BCL2 inhibitor exposure Across dose cohorts, 1 DLT of grade 4 thrombocytopenia occurred Sonrotoclax + azacitidine demonstrated antileukemic activity in patients with R/R AML in all dose cohorts 			
(n=7)(n=6)(n=4)(n=8)Study follow-up, median (range), months 15.4 19.9 ($9.2-30.1$) 0.9 ($1.5-31.7$) 6.8 ($0.7-2.1$)Age, median (range), years 64.0 ($36-80$) 70.0 ($54-78$) 57.5 ($52-70$) 52.5 ($36-71$)	Sonro 160 mg (n=3)Sonro 160 mg (n=6)Sonro 160 mg (n=9)Sonro 320 mg (n=6)All R/R AML (n=2)All R/R AML (N=51)The AML (N=51)Aza 1.7 (1.5-1.7) 5.8 (4.6-7.1) 4.9 (1.2-21.8) 3.8 (1.0-7.6) 7.4 (2.6-12.2) 5.8 (0.2-31.7) -7.6 (0.2-31.7) 54.0 (27-67) 53.0 (42-66) 57.0 (29-69) 66.5 (44-74) 70.0 (67-73) 60.0 (27-80) -7.6 (27-80)	 infestations (azacitidine, n=4; sonrotoclax, n=4) The most common TEAEs leading to dose reduction were neutropenia (sonrotoclax reduction, n=5) and neutrophil count decreased (azacitidine reduction, n=1) Six patients had a TEAE leading to death; the 30-day mortality rate was 2% Two of these TEAEs were considered related to sonrotoclax, azacitidine, and disease (neutropenic sepsis [160 mg x 28 day], pneumonia [320 mg x 14 day]) Two TEAEs leading to death were related to PD (pulmonary mucormycosis [160 mg x 14 day], bone marrow failure [160 mg x 28 day]) The TEAEs of aorto-bronchial fistula (160 mg x 28 day) and Klebsiella sepsis (160 mg x 10 day) leading to death were not related to reatment or disease 				
Male sex, n (%) 3 (43) 3 (50) 2 (50) 5 (63) AML type, n (%)		One DLT (grade 4 thrombocytopenia) occurred in the azacitidine + sonrotoclax 320 mg x 14 day cohort No cases of laboratory or clinical TLS were reported	 The ORR was 54%, of which CR was achieved by 24% and CR/CRh by 42%, and the transplant rate was 20% 			
De novo 7 (100) 4 (67) 2 (50) 7 (88)	1 (33) 6 (100) 8 (89) 6 (100) 1 (50) 42 (82) Tab	ole 3. TEAE Summary	 The study stopping criteria has not been met in any of the dose cohorts Safety expansion of x 14-day dosing is ongoing in 80 mg, 160 mg, and 320 mg cohorts to determine the recommended phase 2 dose 			
Secondary 0 2 (33) 2 (50) 1 (13) HMA failure, n (%) 0 0 1 (25) 1 (13)		All R/R AML				
AML risk stratification, n (%)		(N=51) y TEAEs 50 (98)	Table 4. Summary of Disease Responses ^a			
Favorable 1 (14) 1 (17) 0 1 (13)	0 0 2 (22) 0 0 5 (10) Gra	rade ≥3	Sonro Sonro Sonro Sonro Sonro Sonro Sonro Sonro Sonro Sonro 40 mg 80 mg 80 mg 160 mg 160 mg 160 mg 160 mg 320 mg 320 mg			
Intermediate 3 (43) 1 (17) 2 (50) 4 (50)	0 2 (33) 2 (22) 0 0 14 (27) Seri	erious TEAEs 37 (73)	$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$			
Adverse 3 (43) 4 (67) 2 (50) 3 (38)	3 (100) 4 (67) 5 (56) 6 (100) 2 (100) 32 (63)	AEs leading to death ^a 6 (12)	Aza			
Positive genetic abnormality, n (%) 6 (86) 5 (83) 2 (50) 7 (88)	2 (67) 5 (83) 7 (78) 5 (83) 2 (100) 41 (80) TEAE	AEs leading to discontinuation	CR, n (%) 2 (29) 3 (50) 1 (33) 2 (25) 0 2 (33) 2 (22) 0 0 12 (24) Time to CR, median 3.2 4.1 0.8 3.2 1.4 1.3 1.9			
NPM1 2 (29) 1 (17) 0 2 (25)	0 0 3 (33) 1 (17) 0 9 (18) Aza	za 7 (14)	(range), months (1.5-4.9) (3.7-4.6) (0.8-0.8) (1.9-4.4) (0.9-1.9) (1.1-1.4) (0.8-4.9)			
<i>TP53</i> aneuploidy 0 0 1 (25) 0	0 1 (17) 0 1 (17) 1 (50) 4 (8) Son	onro 7 (14)	Duration of CR, median 7.7 18.0 NR 20.5 NR 0.1 13.1 (95% CI), months ^b (2.3-NE) (1.9-NE) (NE-NE) (NE-NE) (NE-NE) (NE-NE) (0.1-20.5)			
-17/abn(17p); <i>TP53</i> 1 (14) 1 (17) 0 0	0 0 0 0 0 2 (4) TEAE	AEs leading to reduction	CR/CRh, n (%) 5 (71) 4 (67) 1 (33) 3 (38) 0 2 (33) 2 (33) 1 (50) 21 (42) Time to CR/CRh, 2.4 3.9 0.8 1.9 1.4 1.1 1.9 7.7 1.9			
abnormality 1(11) 1(17) 0 0 0 2 (25)	0 1 (17) 2 (22) 0 0 6 (12) Aza	za 1(2)	median (range), months (1.2-3.5) (1.1-4.6) (0.8-0.8) (1.0-1.9) (0.9-1.9) (0.8-1.4) (1.3-2.4) (7.7-7.7) (0.8-7.7)			
<i>IDH1</i> 0 2 (33) 0 2 (25)	0 0 1 (11) 1 (17) 0 6 (12) Son	onro 7 (14)	median (95% Cl), months ^b (4.0-NE) (1.9-NE) (NE-NE) (NE-NE) (NE-NE) (0.1-NE) (NE-NE) (NE-NE) (1.9-20.5)			
<i>IDH2</i> R172 1 (14) 1 (17) 0 1 (13)		AEs leading to interruption	CR/CRi, n (%) 4 (57) 4 (67) 1 (33) 3 (38) 0 2 (33) 3 (33) 3 (50) 1 (50) 21 (42) Time to CR/CRi, median 2.0 3.0 0.8 1.0 1.4 1.1 1.2 7.7 1.3			
<i>FLT3</i> -ITD high AR 0 0 0 0	0 0 0 1 (17) 1 (50) 2 (4) Aza	za 3 (6)	(range), months (1.2-3.2) (1.1-4.1) (0.8-0.8) (0.8-1.9) (0.9-1.9) (0.8-1.4) (0.9-1.3) (7.7-7.7) (0.8-7.7)			
<i>FLT3</i> -ITD low AR 0 1 (17) 0 1 (13)	0 1 (17) 0 0 0 3 (6) Son		median (95% CI), months ^b (4.0-NE) (1.9-NE) (NE-NE) (NE-NE) (NE-NE) (NE-NE) (0.1-NE) (0.1-NE) (NE-NE) (1.9-20.5)			
<i>FLT3</i> -TKD 0 0 1(25) 0	0 0 1 (11) 0 0 2 (4) ^a TEAEs	Es leading to death were aorto-bronchial fistula, bone marrow failure, <i>Klebsiella</i> sepsis, neutropenic sepsis (related to aza and sonro), pneumonia (related to and sonro), pneumonia (related to add sonro), pneumonia (related to add sonro), pneumonia (related to add sonro), and pulmonary mucormycosis.	^a Responses were determined using the 2017 European LeukemiaNet criteria and partial hematology recovery criteria for AML. ^b Medians were estimated using the Brookmeyer and Crowley method with log-log transformation. aza, azacitidine; CRh, CR with partial hematologic recovery; CRi, CR with incomplete hematologic recovery; NE, not estimable, NR, not reached;			
-5 or del(5q) 0 1 (17) 0 1 (13)		izacitidine; sonro, sonrotoclax.	sonro, sonrotoclax.			
Prior therapy	Figu	ure 3. TEAEs in ≥20% (All Grades) or ≥10% (Grade ≥3)	Figure 4. Response Rates			
Prior aza exposure, n (%) 0 0 1 (25) 0	1 (33) 1 (17) 1 (11) 2 (33) 1 (50) 7 (14)		ORR ^a 54%			
No. of lines of prior systemic therapy, 1.0 (1-2) 1.0 (1-2) 2.0 (1-2) median (range)	2.0 (1-2) 2.0 (1-6) 1.0 (1-3) 2.0 (1-3) 1.5 (1-2) 2.0 (1-6) Thro	Neutropenia* 59 ombocytopenia* 2 45	100 24			
AR, allelic ratio; aza, azacitidine; ITD, internal tandem duplication; sonro, sonrotoclax; T			80			


Table 2. Treatment Exposure in R/R AML

	Sonro 40 mg × 10 d (n=7)	Sonro 80 mg × 10 d (n=6)	Sonro 80 mg × 14 d (n=4)	Sonro 160 mg × 10 d (n=8)	Sonro 160 mg × 14 d (n=3)	Sonro 160 mg × 21 d (n=6)	Sonro 160 mg × 28 d (n=9)	Sonro 320 mg × 14 d (n=6)	Sonro 320 mg × 21 d (n=2)	All R/R AML (N=51)	
	Aza										
No. of cycles,	2.0	10.5	1.0	2.5	1.0	2.0	2.0	2.0	3.5	2.0	
median (range)	(2.0-15.0)	(1.0-28.0)	(1.0-1.0)	(1.0-20.0)	(1.0-2.0)	(1.0-7.0)	(1.0-4.0)	(1.0-5.0)	(1.0-6.0)	(1.0-28.0)	
Average cycle	34.5	32.7	26.5	35.0	34.0	36.8	35.0	40.7	42.3	35.0	
duration, median	(29.5-	(21.0-	(22.0-	(5.0-	(23.0-	(25.0-	(25.3-	(26.5-	(35.7-	(5.0-	
(range), days	41.5)	40.9)	44.0)	48.7)	44.0)	53.0)	55.0)	46.0)	49.0)	55.0)	
Relative dose	97.4	81.1	100	100	100	79.6	84.6	81.1	82.1	97.4	
intensity (sonro),	(26.0-	(57.0-	(100-	(33.9-	(90.9-	(54.9-	(22.0-	(47.2-	(64.3-	(22.0-	
median (range), %	100)	112.7)	100)	100)	100)	100)	156.0)	100)	100)	156.0)	
Relative dose	100	87.4	100.2	99.8	100	99.5	100	99.8	92.7	99.9	
intensity (aza),	(52.3-	(45.8-	(99.8-	(73.0-	(85.2-	(64.9-	(69.9-	(60.5-	(84.3-	(45.8-	
median (range), %	100.3)	101.0)	101.5)	101.1)	100.0)	103.4)	100.9)	100.3)	101.1)	103.4)	

aza, azacitidine; sonro, sonrotoclax

Safety


- An overall summary of TEAEs in patients with R/R AML is shown in **Table 3**
- The most common any-grade TEAEs were neutropenia (including neutrophil count decreased),
- thrombocytopenia (including platelet count decreased), and nausea (**Figure 3**) - Neutropenia was the most common grade \geq 3 TEAE and grade \geq 3 infections and infestations
- occurred in 24 patients (47%)



^aNeutropenia includes the terms *neutropenia* and *neutrophil count decreased*. ^bThrombocytopenia includes the terms *thrombocytopenia* and *platelet* count decreased. ^c Sepsis is a grouped term excluding fungal sepsis

Antileukemic Activity

- CR/CRh was achieved in 42% of patients by a median time to CR/CRh of 1.9 months (**Table 4**) - The median duration of response was 13.1 months for CR (median follow-up, 20.8 months), CR/CRh (median follow-up, 3.5 months), and CR/CR with incomplete hematologic recovery (CRi; median follow-up, 3.5 months)
- The ORR was 54% in patients with R/R AML (**Figure 4**)



(N=50)

^a ORR included CR, CRi, MLFS, and PR. CRi, CR with incomplete hematologic recovery; MLFS, morphologic leukemia-free state; ND, not done; NE, not evaluable.

REFERENCES

1. Shimony S, et al. Am J Hematol. 2023;98(3):502-526 4. Venetoclax. Prescribing information. AbbVie, Inc. 2022. 2. Yi M, et al. J Hematol Oncol. 2020;13(1):72 5. Hu N, et al. AACR 2020. Abstract 3077.

DISCLOSURES

PM: Consultancy: Astellas, Agios, Tolero Pharmaceutical, Glycomimetics, Forma Therapeutics, BMS/Celgene, Daiichi Sankyo; Research funding: AbbVie, Astellas, BMS/Celgene, Daiichi Sankyo, Janssen, Karyopharm, Novartis, Pfizer, Teva; Speakers bureau: AbbVie, Astellas, BMS/Celgene, Daiichi Sankyo, Incyte, Janssen, Novartis, Pfizer, Sanofi, Servier, Teva. JS: Consulting/advisory: BMS, Astellas, Otsuka; Research funding: Astex; Speakers bureau: Novartis, Mundipharma. **TFN:** Travel, accommodations, or expenses: Janssen, Novartis, Sobi. **DMS:** Consulting or advisory role: AbbVie, Astellas, Boston Gene, BMS, Daiichi Sankyo, MorphoSys, Sellas; Speakers bureau: BMS, GSK, ThermoFisher, Servier. SL: Consulting or advisory role: BeiGene. CYF: Consulting or advisory role: AbbVie, Novotech, Adaptive, Amgen, Servier, Pfizer, Otsuka, Celgene, Jazz, Astellas; Research funding: Astellas, Jazz; Speakers bureau: AbbVie, Amgen, Pfizer; Travel, accommodations, or expenses: Gilead/Kite. UP: Honoraria: Novartis, BMS, Janssen, AbbVie, Curis, Geron, Jazz, Akeso, Gilead, Servier; Consulting or advisory role: AbbVie, BMS, Janssen, Novartis, GSK, Hemavant; Speakers bureau: Novartis, BMS, Janssen, Jazz, Takeda, Sobi, Blueprint, AstraZeneca; Travel, accommodations, or expenses: AbbVie, Janssen. AHW: Consultancy: Servier, BeiGene, AbbVie, Novartis; Research funding: Novartis, AbbVie, Servier, Janssen, BMS, Syndax, Astex, AstraZeneca, Amgen; Honoraria: Novartis, AstraZeneca, Astellas, Janssen, Amgen, Roche, Pfizer, AbbVie, Servier, Gilead, BMS, Shoreline, Macrogenic, Agios; Patents and royalties: Servier; Speakers bureau: AbbVie, Novartis, BMS, Servier, Astellas; Travel, accommodations, or expenses: Novartis, Servier. AG: Employment: BeiGene, ICON (self), Adaptive Biotechnologies, Notch Therapeutics (spouse); Stock or other ownership: BeiGene (self), Adaptive Biotechnologies (spouse). KS: Employment: BeiGene; Research funding: Incyte, Jazz; Consulting role: Nkarta, Jazz; Honoraria and travel expenses: BMS; Expert testimony: Nelson and Mullins; Data safety monitoring board: Karyopharm; Stock or stock options: BeiGene. CD: Honoraria: Daiichi Sankyo, Astellas, Gilead, Loxo; Consulting or advisory role: GSK, Rigel, AbbVie, GenMab, AstraZeneca, Servier, Schrodinger; Research funding: AbbVie, BMS, Loxo, Astex, Schrodinger, BeiGene, Foghorn. SC, YL, AA: Current

ACKNOWLEDGMENTS

employment and current equity holder in publicly traded company: BeiGene. **PC:** Nothing to disclose.

B. Bazarbachi A. Bone Marrow Transplant. 2022;57(2):147-148.

The authors thank the patients and their families, investigators, co-investigators, and the study teams at each of the participating centers. This study was supported by BeiGene. Medical writing was provided by Kendall Foote, PhD, of Nucleus Global, an Inizio company, and supported by BeiGene.

Presented at the EHA2024 Hybrid Congress; June 13-16, 2024; Madrid, Spain